Yahoo Finance • 6 months ago

Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash... Full story